Table 1.
Summary of MOS-HIV effect sizes overall and in treatment naïve and treatment-experienced HIV-infected patients
| Study | Treatment |
Physical health summary |
Mental health summary |
||||
|---|---|---|---|---|---|---|---|
| Mean change | % change | Effect size | Mean change | % change | Effect size | ||
| Bucciardini et al. 2007 [13] |
ddI/d4T/EFV |
4.7 |
9.4% |
−0.43 |
4.0 |
8.2% |
−0.40 |
| ddI/d4T/NFV |
0.7 |
1.5% |
−0.05 |
2.8 |
5.8% |
−0.28 |
|
| ddI/d4T/EFV/NFV |
2.0 |
4.2% |
−0.17 |
0.0 |
0.0% |
0.00 |
|
| Stangl et al. 2007a[23] |
HAART + weekly home visits |
15.0* |
38.3% |
−1.53 |
14.2* |
35.5% |
−1.27 |
|
Average for treatment-naïve patients [weighted] |
2.5 |
0.1 |
−0.55 |
2.3 |
0.1 |
−0.49 |
|
| Nuesch et al. 2009b[17] |
Continuous treatment |
−1.3 |
−2.4% |
0.20 |
0.8 |
1.5% |
0.03 |
| Scheduled treatment interruptionsc |
−1.2 |
−2.2% |
0.19 |
0.4 |
0.8% |
−0.15 |
|
| Huang et al. 2008 [14] |
TPV/r (tipranavir / ritonavir) |
0.2 |
0.4% |
−0.02 |
1.4 |
2.9% |
−0.13 |
| CPI/r (boosted comparitor PI) |
−0.3 |
−0.6% |
0.03 |
1.7 |
3.6% |
−0.17 |
|
| Powers et al. 2006 [18] |
Intermittent groupd |
0.6 |
1.1% |
−0.07 |
3.2* |
5.9% |
−0.37 |
| Continuous groupe |
1.0 |
1.9% |
−0.09 |
3.2 |
5.9% |
0.00 |
|
|
Average for treatment-experienced patients [weighted] |
−0.2 |
0.0 |
0.04 |
1.5 |
0.0 |
−0.13 |
|
| Overall mean [weighted] | 0.7 | 0.1 | −0.19 | 1.8 | 0.1 | −0.27 | |
Mean change calculated as final score – baseline score. % change calculated as [(final score - baseline score) / baseline score] × 100. Effect size calculated as (final score – baseline score) / standard deviation of baseline score.
*P<0.05; Note: significance of mean change scores not available for all studies; aProspective non-randomized controlled trial; bPatient population includes treatment-naïve and treatment-experienced patients (analyzed together); cCD4-guided treatment with threshold of 350 cells/μL for interruption/re-initiation of ARV therapy; d7 cycles of 4 weeks off/8 weeks on HAART; eContinue HAART regimen for 22 weeks.